Sydnexis Announces New Data from Phase 3 STAR Trial of SYD-101 Presented at 2026 AAPOS Annual Meeting

AI Briefing

• – Sydnexis announces new data from Phase 3 STAR trial of SYD-101 for pediatric progressive myopia
• – Data supports efficacy of low-dose atropine formulation in reducing myopia progression
• – Results presented at 51st Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus